Time to Uveitis Control with Methotrexate and Mycophenolate Mofetil

Uveitis is a group of sight-threatening intraocular inflammatory diseases responsible for 5% to 20% of legal blindness in developed countries.1 Timely control of inflammation is essential to prevent serious complications, and corticosteroid therapy is the mainstay of treatment for noninfectious uveitis. However, long-term exposure to corticosteroids has undesirable ocular and systemic side effects.2 Among the available corticosteroid-sparing treatment options, the antimetabolites methotrexate and mycophenolate mofetil (MMF) are used commonly.